Alan Clucas - Concepedia

Author

Alan Clucas

Fondation Sophia Antipolis

Also Known As

A CLUCAS, A Clucas, A. Clucas, Alan Clucas, Alan T Clucas, Alan T. Clucas, P Kerckhoffs

Publications

842

Citations

H-Index

Concepts

All Affiliations

Fondation Sophia Antipolis Galderma (France)Gouvernance, Risque, Environnement, Développement Pfizer (United States)

About

Alan Clucas is an author at Fondation Sophia Antipolis specializing in medicine, dermatology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	290
2	Pharmacology	5	5	193
3	Immunology	1	1	37
4	Autoimmune Disease	1	1	37
5	Autoimmunity	1	1	37

Alan Clucas

Publications

565

Citations

H-Index

Page 1

	Year	Citations
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus Jonathan I. Silverberg, Andreas Pinter, Grażyna Pulka, Journal of Allergy and Clinical Immunology	2019	262
Adapalene 0.1% gel has low skin-irritation potential Michèle Verschoore, Michel Poncet, Janusz Czernielewski, Journal of the American Academy of Dermatology Topical DrugWound HealingDermatologyAdapalene 0.1Medicine	1997	52
Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients Danièle Caron, Valérie Sorba, Nabil Kerrouche, Journal of the American Academy of Dermatology OphthalmologyCutaneous BiologyClinical DermatologyDermatologyExperimental Dermatology	1997	45
Phase I Evaluation of the Safety,??Pharmacokinetics and Pharmacodynamics of CP-481,715 Alan Clucas, Ajit Shah, Yuanchao Zhang, Clinical Pharmacokinetics Medicinal ChemistryMedicinePharmacotherapyPharmacologyPhysiologically-based Pharmacokinetic Modeling	2007	42
Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel Catherine Queille‐Roussel, Michel Poncet, Stephane Mesaros, Clinical Therapeutics MedicineTopical DrugErythromycin/tretinoin SolutionSkin PharmacologyWound Healing	2001	40
Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients Alan Clucas, Michèle Verschoore, Valérie Sorba, Journal of the American Academy of Dermatology PharmacologyTopical DrugClinical DermatologyWound HealingDermatology	1997	40
CCR1 antagonists for the treatment of autoimmune diseases. Ronald P. Gladue, Samuel H. Zwillich, Alan Clucas, PubMed Chemokine Receptor Ccr1Chemokine BiologyImmunologyImmunotherapyInflammation	2004	37
Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments Danièle Caron, Valérie Sorba, Alan Clucas, Journal of the American Academy of Dermatology MedicineCutaneous BiologyTopical DrugClinical DermatologySkin Pharmacology	1997	34
Evaluation of the effect of the specific CCR1 antagonist CP‐481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects Jeanett Borregaard, Lone Skov, Lisy Wang, Contact Dermatitis	2008	13

Page 1